MarketCap
Facebook
X
TelegramAdamas Pharmaceuticals, Inc. P/E Ratio 2011-2026 | ADMS
Annual P/E Ratio Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -2.85 | -1.34 | -1.82 | -9.9 | -5.38 | -5.99 | 24.4 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.4 | -9.9 | -0.408 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
130 | $ 334.25 | -1.52 % | $ 43.8 B | USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.69 | 1.94 % | $ 8.88 B |  Australia |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-2.73 | $ 7.57 | -13.39 % | $ 74.8 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Burford Capital Limited
BUR
|
12.2 | $ 4.76 | 1.17 % | $ 761 M |  Britain |
 |
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | USA |
 |
Cabaletta Bio
CABA
|
-1.69 | $ 3.3 | 1.23 % | $ 332 M | USA |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 21.26 | -0.56 % | $ 994 M | USA |
 |
BioNTech SE
BNTX
|
6.11 | $ 99.6 | 1.21 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 3.07 | 0.49 % | $ 5.05 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-62.5 | $ 1.55 | -0.64 % | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-5.58 | $ 4.18 | 0.84 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-213 | $ 24.43 | -2.63 % | $ 3.11 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-0.544 | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
3.63 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.47 | -1.01 % | $ 391 M | Britain |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-0.0669 | $ 2.7 | 2.27 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | Israel |
 |
bluebird bio
BLUE
|
-0.316 | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
706 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-0.873 | - | - | $ 1.41 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-467 | $ 4.6 | -0.65 % | $ 310 B | Britain |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
Baudax Bio
BXRX
|
-0.0133 | - | 0.59 % | $ 63 K | USA |